FindTrial
Sign In

Platinum

DRUG20 trials

Sponsors

Fondazione Humanitas per la Ricerca, Oncozyme Pharma Inc., Xinjiang Medical University, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center

Conditions

Breast NeoplasmsCervical CancerEsophageal CancerGastric-type Endocervical AdenocarcinomaHypopharyngeal CancerLimited Stage Small Cell Lung CancerLung CancerLung Neoplasms

Phase 1

Trial of BMS-986012 in Combination With Platinum and Etoposide
CompletedNCT02815592
Bristol-Myers SquibbSmall Cell Lung Cancer
Start: 2016-11-28End: 2024-08-06Updated: 2024-09-04
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
Active, not recruitingNCT03567642
Memorial Sloan Kettering Cancer CenterLung Cancer
Start: 2018-06-12End: 2026-06-30Updated: 2025-07-03
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Active, not recruitingNCT04420884
TakedaSolid Neoplasms
Start: 2020-07-22End: 2026-03-31Updated: 2025-06-13

Phase 2

An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients
CompletedNCT01844791
Oncozyme Pharma Inc.Non-small Cell Lung Cancer
Start: 2012-09-30End: 2014-01-31Updated: 2014-10-21
Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer
NCT02489409
Xinjiang Medical UniversityBreast Neoplasms
Start: 2015-10-31End: 2018-07-31Target: 120Updated: 2017-07-17
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）
NCT04453930
Peking Union Medical College HospitalSmall Cell Lung Carcinoma
Start: 2020-06-08End: 2023-06-30Target: 60Updated: 2020-07-01
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
Active, not recruitingNCT05844150
Biotheus Inc.SCLC
Start: 2023-06-01End: 2025-12-31Updated: 2025-03-12
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
Not yet recruitingNCT06128460
Obstetrics & Gynecology Hospital of Fudan UniversityCervical Cancer
Start: 2023-12-01End: 2029-12-01Target: 24Updated: 2023-11-30
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
RecruitingNCT06256237
Shanghai Pulmonary Hospital, Shanghai, ChinaLimited Stage Small Cell Lung Cancer
Start: 2024-04-01End: 2032-01-31Target: 30Updated: 2024-05-29
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
Not yet recruitingNCT06648200
Shanghai Pulmonary Hospital, Shanghai, ChinaSmall Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
Start: 2024-11-01End: 2030-09-01Target: 100Updated: 2024-10-18
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC
RecruitingNCT06969027
Shanghai Junshi Bioscience Co., Ltd.Non-small Cell Lung Cancer
Start: 2025-06-19End: 2027-12-31Target: 84Updated: 2025-07-04
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033
Not yet recruitingNCT07097948
Shanghai Pulmonary Hospital, Shanghai, ChinaPostoperative Incidental Small Cell Lung Cancer, Toripalimab Adjuvant Therapy Evaluation
Start: 2025-08-31End: 2030-07-31Target: 40Updated: 2025-08-01
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
Not yet recruitingNCT07376499
China Medical University, ChinaSmall Cell Lung Cancer
Start: 2026-01-25End: 2027-06-30Target: 31Updated: 2026-01-29
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
Not yet recruitingNCT07497074
Jiangsu Alphamab Biopharmaceuticals Co., LtdCervical Cancer
Start: 2026-04-01End: 2028-06-01Target: 78Updated: 2026-03-27

Phase 3

Randomized Gefitinib Trial
CompletedNCT00807066
Fondazione Humanitas per la RicercaNon Small Cell Lung Cancer
Start: 2008-11-30End: 2010-10-31Updated: 2012-04-23
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
CompletedNCT03607539
Innovent Biologics (Suzhou) Co. Ltd.Lung Neoplasms
Start: 2018-08-23End: 2023-02-13Updated: 2023-02-27
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
RecruitingNCT03731442
Chinese Academy of Medical SciencesEsophageal Cancer
Start: 2018-11-01End: 2027-10-31Target: 300Updated: 2018-12-12
Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial
NCT04502641
Sun Yat-sen UniversityHypopharyngeal Cancer
Start: 2020-08-01End: 2025-08-01Target: 160Updated: 2020-08-06
Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma
Not yet recruitingNCT06870565
Women's Hospital School Of Medicine Zhejiang UniversityCervical Cancer, Gastric-type Endocervical Adenocarcinoma
Start: 2025-03-31End: 2030-12-31Target: 238Updated: 2025-03-17

Phase 4

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
Not yet recruitingNCT06951841
China Medical University, ChinaSmall Cell Lung Cancer
Start: 2025-04-30End: 2027-06-30Target: 31Updated: 2025-04-30

Related Papers

Population-Based Modeling to Predict Human PK/PD of TAK-500, an Anti-CCR2 Antibody-Drug Conjugate for First-in-Human Study in Cancer Patients.
2026-04-01
Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN).
Journal of Clinical Oncology2025-05-281 citations
Abstract LB397: Biomarker-guided dose selection in the iintune-1 study of dazostinag,a STING agonist, alone and in combination with pembrolizumab for patients with metastatic solid tumors
Cancer Research2025-04-25
Abstract 7143: Development of a peripheral dazostinag (TAK-676) activation RNASeq signature to evaluate STING pharmacodynamic modulation in human solid tumor clinical trials
Cancer Research2025-04-211 citations
Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial.
2025-01-272 citations
Radiomics Models Derived From Arterial-Phase-Enhanced CT Reliably Predict Both PD-L1 Expression and Immunotherapy Prognosis in Non-small Cell Lung Cancer: A Retrospective, Multicenter Cohort Study.
2024-07-317 citations
Osimertinib, platinum, etoposide as initial treatment for patients with <i>EGFR</i> mutant lung cancers with <i>TP53</i> and <i>RB1</i> alterations.
Journal of Clinical Oncology2024-06-016 citations
Benchmarking the transcriptomic predictive biomarkers for immunotherapy plus chemotherapy: Results from phase III RATIONALE-309 and ORIENT-11 randomized trials.
Journal of Clinical Oncology2024-06-01
Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in large population of non-small cell lung cancer.
Journal of Clinical Oncology2024-06-01
69P Biomarker-driven TAM RTK inhibitor plus immunotherapy would benefit NSCLC in first-line setting: Implications from phase III ORIENT-11 trial
ESMO Open2024-03-01
Disparities in African-American patient enrollment in pivotal phase 3 immunotherapy trials that led to FDA drug approval in patients with non-small cell lung cancer.
JCO Global Oncology2023-08-01
Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
Frontiers in Immunology2023-04-1115 citations
High levels of <scp>AXL</scp> expression in untreated <scp><i>EGFR</i></scp>‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
Cancer Science2022-09-2820 citations
PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials
BMJ Open Respiratory Research2022-09-012 citations
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.
2022-07-1961 citations
Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors
Cancer Research2022-06-157 citations
Abstract 3448: The IV STING agonist, TAK-676, enhances immune-mediated anti-tumor activity of radiation in syngeneic mouse models
Cancer Research2022-06-153 citations
Abstract CT243: Phase 1 study of TAK-676 + pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN)
Cancer Research2022-06-152 citations
The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework
Frontiers in Oncology2022-06-103 citations
Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors.
Journal of Clinical Oncology2022-06-0118 citations

8 more papers not shown